Treatment of human GBM cells with RXFP1 agonist CTRP8 increased MPG protein levels and MPG activity as determined by MPG molecular beacon assay, while the cellular levels of other BER proteins, including APE1, DNA polymerase β (polβ), and XRCC1, remained unaffected by CTRP8‐mediated RXFP1 activation. This evidence concerns the gene RXFP1 and glioblastoma.